27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
GAITHERSBURG, Md., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer of Altimmune, will present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference, taking place September 11-12 at the Lotte New York Palace Hotel in New York City.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Presentation Details
Date: | Tuesday, September 12 |
Time: | 10:25am Eastern Time |
Location: | Lotte New York Palace Hotel, Kennedy I Ballroom |
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines.
Altimmune ContactsBill EnrightPresident and CEOPhone: 240-654-1450Email: enright@altimmune.comMichael RiceInvestor RelationsPhone: 646-597-6979Email: mrice@lifesciadvisors.com
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.